EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $31.00 target price on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 207.23% from the company’s current […]